Abstract: The disclosure relates to methods of analyzing a post-translationally modified protein of interest using electrophoresis, the methods comprising deglycosylating the protein of interest after labeling.

Abstract: Methods for fabricating protein-encapsulating microgels using hydrocarbon-in-fluorocarbon emulsions can include: (a) combining at least one crosslinkable polymer, at least one crosslinking modulator, and a powder including at least one protein with a hydrocarbon solvent to form a dispersed phase suspension; (b) adding said dispersed phase suspension to a continuous phase solution, wherein said solution includes a fluorocarbon liquid and a fluorosurfactant, to form a combined dispersed phase suspension and continuous phase solution; (c) applying blending forces to said combined dispersed phase suspension and continuous phase solution to form a non-aqueous emulsion having multiple hydrocarbon droplets including said at least one crosslinkable polymer and said powder further including at least one protein in the fluorocarbon liquid; and (d) removing the hydrocarbon solvent and the fluorocarbon liquid from said non-aqueous emulsion to form isolated hydrogel microparticles, wherein said hydrogel microparticles inc

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure is directed to methods for tuning the release profile of a biologic disposed in a hydrogel. Parameters that can be used for the tuning include a molar ratio of a nucleophilic group to an electrophilic group, the number of the nucleophilic groups in the first precursor, the number of the electrophilic groups in the second precursor, the molecular weight of the first precursor, the molecular weight of the second precursor, a weight ratio of the biologic and excipient to the hydrogel, a weight percentage of the biologic in a solid state formulation, and a ratio of surface area to volume of the hydrogel. The methods described herein allow the formation of hydrogel with different release profiles suitable for different therapeutic applications.

Abstract: Non-aqueous membrane emulsion methods for producing polymeric and polymer-coated microparticles are provided. Some embodiments provide methods for producing a sustained release or controlled release microparticle by combining micronized protein powder and a polymer into a hydrocarbon solvent to form a non-aqueous first solution, agitating the first non-aqueous solution to form a suspension, feeding the suspension into a dispersion pump, wherein the suspension is infused through a porous membrane into a continuous phase comprising a fluorocarbon liquid and a fluorosurfactant to form a hydrocarbon-in-fluorocarbon emulsion. The hydrocarbon solvent, the fluorocarbon liquid, and the fluorosurfactant are removed, and the microparticles are collected.

Abstract: The present invention provides methods for fabricating protein-encapsulating microgels using hydrocarbon-in-fluorocarbon emulsions. The non-aqueous emulsion-based microgel fabrication methods can be used for the encapsulation of a wide range of proteins and peptides, including antibodies and antibody-fusion proteins, for therapeutic use with ease of administration.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: Non-aqueous membrane emulsion methods for producing polymeric and polymer-coated microparticles are provided. Some embodiments provide methods for producing a sustained release or controlled release microparticle by combining micronized protein powder and a polymer into a hydrocarbon solvent to form a non-aqueous first solution, agitating the first non-aqueous solution to form a suspension, feeding the suspension into a dispersion pump, wherein the suspension is infused through a porous membrane into a continuous phase comprising a fluorocarbon liquid and a fluorosurfactant to form a hydrocarbon-in-fluorocarbon emulsion. The hydrocarbon solvent, the fluorocarbon liquid, and the fluorosurfactant are removed, and the microparticles are collected.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure provides pharmaceutical formulations comprising one or more antibodies or antigen-binding fragments thereof that bind to the cat allergen Fel d1. The formulations may contain, in addition to the anti-Fel d1 antibody, a buffer, a thermal stabilizer, a viscosity reducer, and a surfactant. In one aspect, co-formulations comprising two anti-Fel d1 antibodies are provided that have acceptable stability and optimal viscosity.

Abstract: The present invention pertains to compositions and methods of making high concentration protein formulations of a therapeutic protein.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present invention pertains to compositions and methods of making high concentration protein formulations of a therapeutic protein.

Abstract: Microparticles containing a core of therapeutic protein and a cortex of a biocompatible and biodegradable polymer, and methods of making and using the microparticles are provided. The extended release of a therapeutic protein from the microparticles in a physiological solution is demonstrated over an extended period of time.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.